UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service
Executive Summary
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”
You may also be interested in...
UK Regulator Plans New & Higher Fees To Ensure Financial Sustainability
The MHRA says pharmaceutical and medical device companies should be confident that planned changes to the fees structure will guarantee them “the high-quality service they expect.”
UK Regulator To Lose 20% Of Staff In Post-Brexit Cost-Cutting Plans
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.